Estrella Immunopharma’s (ESLA) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Estrella Immunopharma (NASDAQ:ESLA) in a research report sent to investors on Monday morning,Benzinga reports. D. Boral Capital currently has a $8.00 price target on the stock.

A number of other equities research analysts also recently weighed in on ESLA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Estrella Immunopharma in a research report on Wednesday, January 28th. Wall Street Zen upgraded Estrella Immunopharma from a “sell” rating to a “hold” rating in a research report on Saturday, January 31st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $8.00.

Estrella Immunopharma Trading Down 5.8%

ESLA stock opened at $1.30 on Monday. The stock’s 50 day simple moving average is $1.39 and its 200 day simple moving average is $1.44. Estrella Immunopharma has a 12-month low of $0.73 and a 12-month high of $3.15. The firm has a market cap of $49.10 million, a P/E ratio of -3.82 and a beta of 0.55.

Estrella Immunopharma (NASDAQ:ESLA) last released its earnings results on Wednesday, November 12th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.06.

Hedge Funds Weigh In On Estrella Immunopharma

An institutional investor recently raised its position in Estrella Immunopharma stock. Geode Capital Management LLC boosted its holdings in Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 8.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 109,808 shares of the company’s stock after acquiring an additional 8,318 shares during the quarter. Geode Capital Management LLC owned 0.29% of Estrella Immunopharma worth $171,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 0.35% of the company’s stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.